Product Microsites for Medical Publishing Compliance

Ananya Rakhecha of QED42 explains that medical and pharmaceutical brands face complex regulatory requirements that strain shared CMS platforms. Each product requires tailored claims, approvals, disclaimers, and detailed medical, legal, and regulatory reviews. Shared systems introduce risks such as overlapping review cycles, unintended content exposure and cumbersome audit log filtering. Ananya argues these challenges slow publishing and increase compliance risk.

Ananya describes product microsites as dedicated publishing spaces that assign each product its own content environment and compliance boundary. Microsites enable scoped review cycles for MLR teams, audience-specific content gating, independent version control and clear audit trails. A QED42 case study demonstrates that rebuilding a top product site as a microsite enhanced update speed and review focus while integrating with DAM, CRM, SSO, and analytics platforms.

The post presents a compelling argument for microsites in regulated publishing, illustrating the benefits with real-world examples. It would be strengthened by quantitative performance metrics, detailed cost analysis and technical architecture diagrams. Including sample workflows and implementation roadmaps would help teams evaluate feasibility. Overall, the article presents a convincing model for scaling regulated content publishing.